HLA-DR antigen is composed of an alpha-beta heterodimer of 35 and 33 Kd respectively. It is highly polymorphic in the human population. GRB1 recognises an epitope shared by all HLA-DR alleles.
| Inventor | Institute |
|---|---|
| Francisco Ruíz-Cabello Osuna, Miguel Ángel López-Nevot, Federico Garrido Torres-Puchol | Virgen de las Nieves University Hospital, The Andalusian Health Service |
| Cat. #: | 161695 |
|---|---|
| Tool sub type: | Primary antibody |
| Cancer types: | Blood cancer |
| Research Fields: | Cancer |
| Application: | FACS; IHC; ELISA; WB |
| Target: | HLA-DR |
| Reactivity: | Human |
| Clone: | GRB1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Primary citation: | Ruiz-Cabello. 1985. Sangre (Barc). 30(2):190-196. PMID: 3859940 |
| Product description: | HLA-DR antigen is composed of an alpha-beta heterodimer of 35 and 33 Kd respectively. It is highly polymorphic in the human population. GRB1 recognises an epitope shared by all HLA-DR alleles. It is expressed in antigen presenting cells: dendritic cells, macrophages and B lymphocytes and in some tumours |
|---|---|
| Isotype: | IgG2ak |
| Molecular weight: | 35 kDa & 33 kDa (68 kDa; heterodimer) |
| Immunogen: | B-ALL cells |
| Storage buffer: | PBS with 0.02% azide |
|---|---|
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Ruiz-Cabello. 1985. Sangre (Barc). 30(2):190-196. PMID: 3859940 |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.